Topics:

ASCO 2012

ASCO 2012

CancerNetwork and the journal ONCOLOGY present an exclusive interview with Dr. Kimberly Blackwell, Duke Cancer Institute, who discusses some of the most important information to come out of this year’s meeting and talks about the future of breast cancer research.

CancerNetwork speaks with Hagop Kantarjian, MD, M.D. Anderson Cancer Center, who shares his impressions of some of the highlights of this year’s ASCO meeting with regard to hematologic malignancies.

Cancer Network presents an exclusive interview with Joel W. Neal, MD, PhD, who discusses some of the most important information to come out of this year’s meeting and talks about the future of lung cancer research.

Impressive interim results from a phase Ib/II trial of ibrutinib, a selective Bruton tyrosine kinase inhibitor, in patients with chronic lymphocytic leukemia (CLL) were reported at ASCO.

Bendamustine plus rituximab should be considered as the preferred first-line treatment of follicular and indolent lymphomas, and the elderly with mantle cell lymphoma.

Updated clinical data from the pivotal phase II global PACE trial of ponatinib confirm its impressive antileukemic activity in patients with chronic myeloid leukemia or Philadelphia-chromosome-positive acute lymphoblastic leukemia at all stages who are resistant or intolerant to dasatinib or nilotinib.

Women previously treated for HER2-positive breast cancer have lower rates of relapse when given a novel peptide vaccine. The AE37 vaccine showed a 43% risk reduction in these patients after 22 months of follow-up in a phase IIb clinical trial.

Pages

Subscribe to ASCO 2012 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.